The board of directors of WuXi Biologics (Cayman) Inc. announced that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the six months ended June 30, 2020, it is expected that the profit attributable to equity shareholders of the Company for the six months ended June 30, 2020 will increase more than 58% compared with the profit attributable to equity shareholders of the Company for the corresponding period of last year. Such increase was primarily attributable to (i) immediate and effective implementation of Business Continuity Plan to minimize the impact of the COVID-19 pandemic on its business and operations; (ii) more client projects were added into the Group's pipeline expediting the development and manufacturing of potential treatments related to COVID-19 in support of its global clients; (iii) utilization improvement of existing capacities, which were partially offset by the ramp-up of new sites, and by the increase of administrative expenses in line with the Group's business growth; and (iv) gains from investments, foreign exchange, tax refund from prior years and other non- operating income recorded.